EP0787015B1 - Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide - Google Patents
Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide Download PDFInfo
- Publication number
- EP0787015B1 EP0787015B1 EP95935689A EP95935689A EP0787015B1 EP 0787015 B1 EP0787015 B1 EP 0787015B1 EP 95935689 A EP95935689 A EP 95935689A EP 95935689 A EP95935689 A EP 95935689A EP 0787015 B1 EP0787015 B1 EP 0787015B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acetylated
- modified
- polygalacturonate
- carrier
- oligogalacturonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 26
- 208000037386 Typhoid Diseases 0.000 title claims abstract description 17
- 201000008297 typhoid fever Diseases 0.000 title claims abstract description 17
- 229960005486 vaccine Drugs 0.000 title claims description 22
- 150000004676 glycans Chemical class 0.000 title abstract description 49
- 229920001282 polysaccharide Polymers 0.000 title abstract description 48
- 239000005017 polysaccharide Substances 0.000 title abstract description 48
- 230000015572 biosynthetic process Effects 0.000 title description 5
- 238000003786 synthesis reaction Methods 0.000 title description 5
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000002163 immunogen Effects 0.000 claims abstract description 33
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 24
- 229920001277 pectin Polymers 0.000 claims description 93
- 239000001814 pectin Substances 0.000 claims description 93
- 235000010987 pectin Nutrition 0.000 claims description 93
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 claims description 63
- 239000000427 antigen Substances 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 241000196324 Embryophyta Species 0.000 claims description 22
- 238000006640 acetylation reaction Methods 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 13
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 10
- -1 tetanus toxoid Proteins 0.000 claims description 10
- 229960000814 tetanus toxoid Drugs 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 8
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 8
- 229940099500 cystamine Drugs 0.000 claims description 8
- 239000002095 exotoxin Substances 0.000 claims description 8
- 231100000776 exotoxin Toxicity 0.000 claims description 8
- 208000002672 hepatitis B Diseases 0.000 claims description 8
- 230000000951 immunodiffusion Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 7
- 241000193468 Clostridium perfringens Species 0.000 claims description 7
- 230000021736 acetylation Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 7
- 230000001900 immune effect Effects 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 7
- YCLSOMLVSHPPFV-UHFFFAOYSA-N 3-(2-carboxyethyldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSCCC(O)=O YCLSOMLVSHPPFV-UHFFFAOYSA-N 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 101710132601 Capsid protein Proteins 0.000 claims description 4
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 4
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 4
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 2
- 241000335053 Beta vulgaris Species 0.000 claims description 2
- 244000141359 Malus pumila Species 0.000 claims description 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 2
- 235000021016 apples Nutrition 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229940118376 tetanus toxin Drugs 0.000 claims description 2
- 108010077805 Bacterial Proteins Proteins 0.000 claims 3
- 201000005702 Pertussis Diseases 0.000 claims 3
- 241000589516 Pseudomonas Species 0.000 claims 3
- 108010067390 Viral Proteins Proteins 0.000 claims 3
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 150000002482 oligosaccharides Polymers 0.000 abstract description 14
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000004044 response Effects 0.000 abstract description 5
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000005847 immunogenicity Effects 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000011800 void material Substances 0.000 description 6
- 125000003047 N-acetyl group Chemical group 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 4
- 150000001718 carbodiimides Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical group O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000010318 polygalacturonic acid Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000006177 thiolation reaction Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000021309 simple sugar Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- VYPPEYAOCURAAE-GUCUJZIJSA-N D-galacto-hexodialdose Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O VYPPEYAOCURAAE-GUCUJZIJSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 229940124857 Salmonella typhi vaccine Drugs 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to immunoprophylaxis and vaccines. More particularly it relates to modifying a plant, fruit or synthetic polysaccharide such that it is immunogenic and may be used as a vaccine to prevent typhoid fever in infants and young children.
- Typhoid fever caused by Salmonella typhi , remains a common and serious disease in many parts of the world.
- the capsular polysaccharide (Vi) is both an essential virulence factor and a protective antigen of Salmonella typhi [19].
- Tacket et al. in J. Infect. Dis. 154: 342-345 (1986) disclose a vaccine made from the Vi capsular polysaccharide of Salmonella typhi. Field trials in Nepal and in the Republic of South Africa showed that a single injection of Vi conferred about 70% protection against typhoid fever in older children and in adults [1,13].
- the mechanism of its protective action similar to other polysaccharide vaccines, is to elicit a critical level of serum antibodies.
- the immunologic properties of the Vi that limits its use as a vaccine are: 1) only ⁇ 70% efficacy in individuals 5 to 45 years of age; 2) an age-dependent serum antibody response, Vi elicited a comparatively short-lived antibody responses in 2 to 5 year old children and only low levels of antibodies in a fraction of children ⁇ 2 years-old and; 3) reinjection did not elicit a booster antibody response (T-cell independent) [15,19].
- T-cell independent To increase its immunogenicity and to induce T-cell dependence, the Vi was conjugated to proteins [22,24,25].
- a clinical trial in adults in the United States showed that Vi-protein conjugates elicited significantly higher levels of serum antibodies than the Vi alone [25].
- the Vi is a linear homopolymer of (1 ⁇ 4)- ⁇ - D -GalA p NAc, variably O-acetylated at C 3 (Fig. 1) [19, 23].
- Whiteside and Baker in J. Immunol. 86:538-542 (1961) and Landy et al., Am. J. Hyg . 73: 55-65 (1961) disclose that the 0-acetyl groups on Vi is essential for its antigenicity.
- Szu et al. disclose a conjugate scheme for Vi capsular polysaccharide covalent bound to a carrier protein (22, 23, 24).
- International Publication No. WO 94/03208 published February 17, 1994, U.S. Patent No. 5,204,098 issued April 20, 1993 and International Publication No.
- WO 93/07178 published April 15, 1993 also disclose Vi capsular polysaccharide-protein carrier conjugates.
- synthesis of Vi-protein conjugates poses several problems.
- Second, standardization of Vi conjugates has been hindered by a lack of a colorimetric method for quantification of this polysaccharide [21]. Colorimetric methods are not applicable to the Vi because the polyhexosaminuronic acid structure resists acid hydrolysis and does not form a chromophore in the carbazole assay.
- the oligo- or polysaccharide is based on pectin which has been modified by acetylation at the C 2 and/or C 3 hydroxyls of its galacturonate subunit.
- methods are provided to synthesize a modified plant, fruit or synthetic oligo- or polysaccharide which is structurally similar to the Vi antigen.
- methods are provided to conjugate the modified plant, fruit or synthetic oligo- or polysaccharide with a carrier.
- Fig. 1 shows the structure of the repeating unit of the Vi, the pectin and the O-acetylated pectin.
- C 2 (R) is N-acetylated and C 3 (R 1 ) is O-acetylated;
- C 2 and C 3 are hydroxylated;
- OAcPec C 2 and C 3 are O-acetylated,
- n number of subunits.
- Fig. 2 shows the methyl resonances on the O-acetylated pectin by 13 C NMR spectroscopy
- Fig. 3 shows the HPLC gel filtration profile of the 0-acetylated pectin -TT conjugate through Superose® 6 in 0.01 sodium phosphate, 0.1M Na2SO4, pH 7.0.
- the refractive index is the upper line and the 280nm absorbance is the lower line.
- Fig. 4 shows the antigenicity of the O-acetylated pectin compared with Vi by double immunodiffusion.
- Center well B-260 Vi antiserum, 1) Vi, 100 ⁇ g/ml; 2) OAcPec K + form; 3) OAcPec Ca ++ form; 4) OAcPec C 2 H 5 N + form.
- Fig. 5 shows the quantitative precipitin analysis of pectin ( ⁇ ), OAcPec ( ⁇ ) and Vi ( ⁇ ).
- Fig. 6 shows the temperature dependent stability of O-acetyls on Vi(---) and O-acetylated pectin (_) at 4oC (o), 22oC ( ⁇ ), 37oC ( ⁇ ), and 60oC( ⁇ ).
- the decrease in extent of O-acetylation is depicted as the % remaining after incubation at the various intervals and temperatures compared to the starting material.
- the Vi molecule of Salmonella typhi has a simple structure which is a linear polysaccharide having repeating sugar subunits.
- the antigenicity and immunogenicity of Vi depends on its N- acetyl at C 2 and O-acetyl at C 3 on each galacturonate subunit [19,23].
- N-acetyl As shown for Vi and other polysaccharides, removal of the O-acetyls removed most of the antigenicity and all of the immunogenicity of the Vi [23,26].
- the precise role of N-acetyl is not known as selective removal of the N-acetyl on Vi has not been accomplished.
- the present invention mimics the simple structure of Vi by modification of plant, fruit or synthetic saccharides.
- the modified plant, fruit or synthetic saccharides resemble Vi in antigenic and immunogenic properties and as such they have the capacity to act as an effective vaccines against typhoid fever.
- the present invention relies on the use of a modified plant, fruit or synthetic oligosaccharide or polysaccharide.
- Oligosaccharide as defined herein is a carbohydrate containing from two to ten simple sugar subunits linked together.
- a polysaccharide as defined herein is a carbohydrate containing more than ten simple sugar subunits linked together.
- the present invention preferably makes use of a modified pectin or modified D-galacturonan, oligogalacturonate or polygalacturonate and mixtures thereof.
- modified pectin or modified oligogalacturonate or polygalacturonate refers to native or naturally occurring pectin or synthetic D-galacturonan, oligogalacturonate and polygalacturonate that has been structurally altered.
- Such structural alterations are any alterations that render the modified pectin or modified D-galacturonan, oligogalacturonate or polygalacturonate antigenically similar to the Vi antigen of Salmonella typhi .
- the structural alterations substantially approximate the structure of the Vi antigen of S. typhi.
- the aforementioned modified pectin, D-galacturonan, oligo-, and polygalacturonate is further characterized by its ability to immunologically mimic an epitope (antigenic determinant) expressed by S. typhi .
- Such a modified pectin, D-galacturonan, oligo-, and polygalacturonate is useful herein as a component in an inoculum for producing antibodies that immunoreact with S. typhi , and preferably immunoreact with the Vi of S. typhi.
- the phrase "immunologically mimic" in its various grammatical forms refers to the ability of the aforementioned modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate to immunoreact with an antibody that recognizes and binds to a native epitope on the Vi of S. typhi as defined herein.
- a subject modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate need not be structurally identical to the Vi antigen so long as it includes the required sterical structure and is able to elicit antibodies that react with the Vi antigen on S. typhi.
- a subject modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate includes any substituted analog, fragment or chemical derivative of a pectin so long as the modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate is capable of reacting with antibodies that react with the Vi antigen. Therefore, a present modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate can be subject to various changes that provide for certain advantages in its use.
- substitution includes the use of a chemically derivatized residue in place of a non-derivatized residue provided that such modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate display the requisite immunological activity.
- “Chemical derivative” refers to a subject modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate having one or more residues chemically derivatized by reaction of a functional side group. Additional residues may also be added for the purpose of providing a "linker” by which the modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate can be conveniently affixed to a label or solid matrix or carrier. Labels, solid matrices and carriers that can be used with the subject modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate are described herein below.
- the present invention makes use of a modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate in which the monosaccharide subunit(s) have one O-acetylated carbon, preferably two O-acetylated carbons.
- the monosaccharide subunit(s) have one O-acetylated carbon, preferably two O-acetylated carbons.
- at least C 3 or C 2 is O-acetylated.
- C 3 and C 2 are O-acetylated.
- at least 50% of C 2 and C 3 are O-acetylated.
- the Vi molecule has N-acetyl groups at position C 2 and O-acetyl groups at position C 3 . If all of the C 2 positions have acetyl groups and all the C 3 positions on Vi contain acetyl groups, then by definition, the Vi molecule is theoretically 200% fully acetylated. In most preparations of Vi the percent acetylation varies.
- the C 2 position is usually about 100% N-acetylated and the C 3 position is from about 60-90% O-acetylated depending on normal variation in preparations of Vi.
- the modified pectin, D-galacturonan, oligogalacturonate and polygalacturonate employed in the present invention approximates the total percent acetylation of Vi.
- modified pectin, D-galacturonan, oligogalacturonate and polygalacturonate employed in the present invention are from about 50% to about 200% O-acetylated, preferably from about 80% to about 200% O-acetylated, more preferably from about 160% to about 190% O-acetylated.
- the modified pectin and the modified D-galacturonan, oligogalacturonate and polygalacturonate employed in the present invention has a molar ratio of O-acetyl groups/mole galacturonan sufficient to elicit antibodies that bind to Vi.
- the molar ratio may be at least 0.5 mole of O-acetyl/mole galacturonan (Gal A), preferably at least 1.6 moles O-acetyl/mole Gal A, more preferably between about 1.6 and about 1.9 moles O-acetyl/mole Gal A. In one embodiment, the ratio is about 1.9 moles O-acetyl/mole Gal A.
- the molecular weight of the Vi alone and as a Vi-carrier conjugate is related to its immunogenicity [16, 17, 22].
- the modified pectin and modified D-galacturonan, oligogalacturonate and polygalacturonate may vary in molecular weight in order to enhance its antigenicity or to enhance its immunogenicity when in a conjugate form.
- the modified pectin and modified D-galacturonan, oligogalacturonate and polygalacturonate may have from about 2 to about 1,000 modified galacturonic subunits, preferably from about 50 to about 800, more preferably from about 200 to about 600 monosaccharide subunits.
- the molecular weight of the modified pectin may range from about 100 to about 1,000,000, preferably from about 200,000 to about 600,000. In one embodiment the molecular weight of the modified pectin is approximately 400 kD.
- substitutions or deletions are encompassed, such that the substitutions or deletions result in a modified pectin and modified D-galacturonan, oligogalacturonate and polygalacturonate that is antigenically similar to the Vi antigen of S. typhi .
- naturally occurring pectin is modified as to replace the hydroxyl groups at the C 2 and C 3 positions of galacturonic acid with O-acetyl groups.
- the modified pectin is referred to herein as OAcPec.
- the characteristics of OAcPec in comparison with Vi of S. typhi is as follows:
- OAcPec and Vi are antigenically indistinguishable by immunodiffusion (Fig. 4). However, OAcPec, unlike Vi, is not immunogenic in mice probably due to its lower molecular weight [16].
- modified pectin, and modified D-galacturonan, oligo-, and polygalacturonate-carrier conjugate is immunogenic to Vi in mammals.
- immunogenic is meant that the modified pectin-carrier conjugate and modified D-galacturonan, oligo-, and polygalacturonate-carrier conjugate elicit the production of antibodies upon injection into mammals.
- the antibodies elicited are capable of specifically reacting or binding to S. typhi, are capable of specifically reacting or binding to the Vi of S. typhi and are capable of providing passive protection against S.
- modified pectin and modified D-galacturonan, oligo-, and polygalacturonate-carrier conjugate of the present invention are capable of inducing a statistically significant rise of antibodies that bind to Vi (booster effect) upon reinjection.
- Modified pectin, and modified D-galacturonan, oligogalacturonate and modified polygalacturonate have several advantages over the Vi in preparing conjugates for vaccines to prevent typhoid fever.
- Special P 3 facilities are required to culture pathogens such as S. typhi. This restricts the availability of Vi and presents safety concerns in preparing a Vi vaccine.
- the present invention of 1) pectin, D-galacturonan, oligo- and polygalacturonate are easy to obtain, safe and purification is simpler than extraction of the Vi from S.
- modified oligo- and polygalacturonate can be measured during the synthesis of the conjugate and in the final container by a colorimetric reaction and; 3) there is no solubility problem and the yield of modified pectin, D-galacturonan, oligo- and polygalacturonate-carrier conjugates is higher than with Vi; 4) at the 4°C, the standard storage temperature of vaccines, the stability of modified pectin, D-galacturonan, oligo- and polygalacturonate is similar to that of the Vi.
- the present invention provides a method to prepare a synthetic Vi antigen from a plant, fruit or synthetic oligo- or polysaccharide and to conjugate it with a carrier in order to enhance and elicit a booster response against Salmonella typhi capsular polysaccharide.
- pectin, D-galacturonan, oligogalacturonate, or polygalacturonate is O-acetylated at C2 and C3 positions with acetic anhydride.
- O-acetylated pectin, D-galacturonan, oligogalacturonate, or polygalacturonate is thiolated with cystamine, or aminolated with adipic dihydrazide, diaminoesters, ethyldiamine and the like.
- Both the thiolated and the aminolated O-acetylated pectin, D-galacturonan, oligogalacturonate, or polygalacturonate are stable, may be freeze dried, and stored in cold.
- the thiolated intermediate may be reduced and covalently linked to a polymeric carrier containing a sulfhydro group, an N-pyridyldithio group.
- the aminolated intermediate may be covalently linked to a polymeric carrier containing a carboxyl group through carbodiimide condensation.
- O-acetylated pectin, D-galacturonan, oligogalacturonate, or polygalacturonate covalently linked to a polymeric carrier is immunogenic in mammals and can serve as a typhoid fever vaccine.
- Pectin extracted and purified from plants or fruits such as, but not exclusive, inner portion of the rind of citrus fruits such as oranges, fruit pomaces as from apples or beets, and the like, can be used as the source of polysaccharide.
- the pectin may be further purified, for example, by precipitation with ethanol or gel filtration and the like.
- Pectin can be O-acetylated by treatment with acetic anhydride in formamide and pyridine. The content of O-acetyl groups can be increased by repeating the acetylation process until the desired level of acetylation is achieved.
- Polymeric carriers Carriers are chosen on the basis of facilitating two functions: 1) to increase the immunogenicity of the polysaccharide and 2) antibodies raised against the carrier are medically beneficial. Carriers that fulfill these criteria are described in the art (7, 10, 22-25).
- Polymeric carriers can be a natural or a synthetic material containing a primary or/and a secondary amino group, an azido group or a carboxyl group.
- the carrier can be water soluble or insoluble. Examples of water soluble carriers include but are not limited to natural or synthetic peptides or proteins from bacteria or virus, e.
- water insoluble carriers include but are not limited to are aminoalkyl-Sepharose® , e. g., aminopropyl or aminohexyl Sepharose® , and aminopropyl glass and the like. Other carriers may be used when an amino or carboxyl group is added through covalent linkage with a linker molecule.
- O-acetylated pectin, D-galacturonan, oligogalacturonate, or polygalacturonate conjugated with a carrier The O-acetylated pectin, D-galacturonan, oligogalacturonate, or polygalacturonate can be covalently bound to a carrier with or without a linking molecule.
- the O-acetylated pectin, D-galacturonan, oligogalacturonate, or polygalacturonate and carrier are mixed in the presence of carboxyl activation agent, such as carbodiimide in a choice of solvent appropriate for both the pectin, D-galacturonan, oligogalacturonate, or polygalacturonate and the carrier as are known in the art.
- carboxyl activation agent such as carbodiimide
- the O-acetylated plant, fruit or synthetic D-galacturonan, oligosaccharide or polysaccharide is preferably conjugated to a carrier using a linking molecule.
- a linker or crosslinking agent as used in the present invention, is a small linear molecule having a molecular weight of approximately ⁇ 500 and is non-pyrogenic and non-toxic in the final product form (7, 10, 22-25).
- a linker or crosslinking agent either or both of the pectin, D-galacturonan, oligogalacturonate, or polygalacturonate and the carrier are covalently bound to a linker first.
- the linkers or crosslinking agents are a homobifunctional or heterobifunctional molecules, e. g., adipic dihydrazide, ethylene diamine, cystamine, N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl N-(2-iodoacetyl)-b-alaninate-propionate (SIAP), succinimidyl 4-(N-Maleimido-methyl) cyclohexane-1-carboxylate (SMCC), 3,3'-dithiodipropionic acid and the like.
- adipic dihydrazide e. g., adipic dihydrazide, ethylene diamine, cystamine, N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl N-(2-iodoacetyl)-
- the linkers are bound to the carboxyl groups of the O-acetylated pectin, D-galacturonan, oligogalacturonate, or polygalacturonate or the carrier through carbodiimide condensation.
- the linkers are bound to the amino groups of the carrier through carbodiimide condensation or N-hydroxylsuccinimidyl ester.
- the unbound materials are removed by gel filtration or ion exchange column depending on the materials to be separated.
- the final conjugate consist of the oligo- or polysaccharide and the carrier bound through a linker.
- the modified pectin-carrier conjugates and modified D-galacturonan, oligogalacturonate and polygalacturonate-carrier conjugates of the present invention elicit antibodies that react with or bind to the Vi antigen.
- the anti-Vi antibody levels elicited by the modified pectin-carrier conjugates were comparable to those elicited by a Vi- Pseudomonas aeruginosa recombinant exoprotein A (rEPA) conjugate as measured by ELISA.
- rEPA Vi- Pseudomonas aeruginosa recombinant exoprotein A
- the modified pectin-carrier and modified D-galacturonan, oligogalacturonate and polygalacturonate-carrier conjugate may be used as an effective vaccine against S. typhi to prevent or ameliorate typhoid fever in humans.
- the present inoculum contains an effective, immunogenic amount of modified pectin-carrier conjugate and modified D-galacturonan, oligogalacturonate and polygalacturonate-carrier conjugates of this invention.
- the effective amount of modified pectin-carrier conjugate and modified D-galacturonan, oligogalacturonate and polygalacturonate-carrier per unit dose sufficient to induce an immune response to the Vi antigen depends, among other things, on the species of mammal inoculated, the body weight of the mammal and the chosen inoculation regimen as is well known in the art.
- Inocula typically contain modified pectin-carrier conjugate and modified D-galacturonan, oligogalacturonate and polygalacturonate-carrier conjugate concentrations of oligo- or polysaccharide of about 1 micrograms to about 100 milligrams per inoculation (dose), preferably about 25 micrograms to about 50 milligrams per dose.
- unit dose refers to physically discrete units suitable as unitary dosages for mammals, each unit containing a predetermined quantity of active material (oligo- or polysaccharide) calculated to produce the desired immunogenic effect in association with the required diluent.
- active material oligo- or polysaccharide
- the specifications for the novel unit dose of an inoculum of this invention are dictated by and are directly dependent on (a) the unique characteristics of the active material and the particular immunologic effect to be achieved, and (b) the limitations inherent in the art of compounding such active material for immunologic use in animals, as disclosed in detail herein, these being features of the present invention.
- Inocula are typically prepared as a solution in tolerable (acceptable) diluent such as water, saline or phosphate-buffered saline or other physiologically tolerable diluent such as water and the like to form an aqueous pharmaceutical composition.
- tolerable (acceptable) diluent such as water, saline or phosphate-buffered saline or other physiologically tolerable diluent such as water and the like to form an aqueous pharmaceutical composition.
- the route of inoculation may be intramuscular, sub-cutaneous and the like, which results in eliciting antibodies protective against S. typhi.
- the dose is administered at least once.
- a second or booster dose may be administered approximately 4 to 6 weeks after the initial injection. Subsequent doses may be administered as indicated.
- antibody in its various grammatical form is used herein to refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope.
- Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and portions of an immunoglobulin molecule, including those portions known in the art as Fab, Fab', F(ab') 2 and F(v) as well as chimeric antibody molecules.
- An antibody combining site or antigen binding fragment is that structural portion of an antibody molecule comprised of a heavy and light chain variable and hypervariable regions that specifically binds (immunoreacts with) an antigen.
- the term immunoreact in its various forms means specific binding between an antigenic determinant-containing molecule and a molecule containing an antibody combining site such as a whole antibody molecule or a portion thereof.
- the antibody is characterized as comprising antibody molecules that immunoreact with: 1) S. typhi , 2) isolated Vi antigen of S. typhi and 3) a modified pectin of the present invention, and being substantially free of antibody molecules that immunoreact with native or naturally occurring pectin.
- the aforementioned antibody is typically produced by immunizing a mammal with an inoculum containing a modified pectin-carrier conjugate and modified D-galacturonan, oligogalacturonate and polygalacturonate-carrier conjugates of this invention and thereby induce in the mammal, antibody molecules having immunospecificity for the immunizing conjugate.
- the antibody molecules are then collected from the mammal.
- the antibody molecules may be polyclonal or monoclonal antibody.
- Monoclonal antibodies may be produced by methods known in the art.
- the antibody may be contained in blood plasma, serum, hybridoma supernatants and the like. Alternatively, the antibody is isolated to the extent desired by well known techniques such as, for example, by using DEAE Sephadex® .
- the antibodies may be purified so as to obtain specific classes or subclasses of antibody such as IgM, IgG, IgA, IgG 1 , IgG 2 , IgG 3 , IgG 4 and the like.
- Antibody of the IgG class are preferred for purposes of passive protection.
- the aforementioned antibodies have a number of diagnostic and therapeutic uses.
- the antibodies can be used as an in vitro diagnostic agent to test for the presence of S. typhi in biological samples in standard immunoassay protocols.
- assays include, but are not limited to, radioimmunoassays, EIA, fluorescence assay, Western blot and the like.
- the biological sample is contacted to said antibodies and a labelled second antibody is used to detect the presence of S. typhi, or the Vi antigen of S. typhi to which the antibodies are bound.
- Such assays may be, for example, of direct format (where the labelled first antibody is reactive with the antigen), an indirect format (where a labelled second antibody is reactive with the first antibody), a competitive format (such as the addition of a labelled antigen), or a sandwich format (where both labelled and unlabelled antibody are utilized), as well as other formats described in the art.
- the antibodies and antigen binding fragments referred to above are useful in prevention and treatment of infections and diseases caused by S. typhi and other microorganisms that have structures immunologically similar to the Vi antigen.
- the dosage of administered antibodies or antigen binding fragments will vary depending upon such factors as the mammal's age, weight, height, sex, general medical condition, previous medical history and the like.
- a dosage of antibodies or antigen-binding fragments which is in the range of from about 1 mg/kg to about 10 mg/kg body weight of the mammal, although a lower or higher dose may be administered.
- the antibodies or antigen-binding fragments referred to above are intended to be provided to the recipient subject in an amount sufficient to prevent, lessen or attenuate the severity, extent or duration of the infection by S. typhi.
- the administration of the agents of the invention may be for either "prophylactic” or "therapeutic" purpose.
- the agents are provided in advance of any symptom.
- the prophylactic administration of the agent serves to prevent or ameliorate any subsequent infection.
- the agent is provided at (or shortly after) the onset of a symptom of infection.
- the agent of the present invention may, thus, be provided either prior to the anticipated exposure to S. typhi (so as to attenuate the anticipated severity, duration or extent of an infection and disease symptoms) or after the initiation of the infection.
- modified pectin, modified D-galacturonan, oligogalacturonate, polygalacturonate, alone or linked to a carrier, as well as antibodies and other necessary reagents and appropriate devices and accessories may be provided in kit form so as to be readily available and easily used.
- Pectin (GENU pectin, from Copenhagen, Denmark, type LM-1912CSZ) was extracted from citrus. Pyrogen-free water (PFW) and pyrogen-free saline (PFS) for clinical use were from Baxter, Deerfield, WI; N-succinimidyl 3(2-pyridyldithio) propionate (SPDP) from Pierce, Rockford, IL; formamide, cystamine from Fluka, Ronkoncoma, NY; pyridine, NaOH, HCl from Baker Chemical, Philipsburg, NJ, acetic anhydride, dithiothreitol (DTT), EDTA, 1-ethyl-3(d-dimethylaminopropyl) carbodimide (EDAC), acetyl choline, BSA, dithionitrobenzoic acid (Ellman reagent), D-galacturonic acid monohydride (GalA) and tetrabutylammonium hydroxide
- rEPA Pseudomonas aeruginosa recombinant exoprotein A
- Pectin was dissolved in PFW (10 mg/mL) at 60°C for 1 hour, cooled to room temperature and adjusted to pH 7.0 with 1M NaOH. The polysaccharide was precipitated twice with 75% ethanol and then freeze-dried. Pectin so treated contained less than 1% of protein and nucleic acid [28]. O-acetylation of pectin was performed as described [6]. Briefly, pectin (1 g) was suspended in formamide (20 mg/mL) at 50°C for 1 hour, 20 mL pyridine added, mixed and cooled to room temperature. Acetic anhydride (15 mL) was added dropwise with mixing at room temperature for 2 hours. The reaction mixture was poured into cold absolute ethanol.
- the precipitate was filtered, dissolved in PFW and dialyzed at 3 to 8°C against multiple changes of deionized water and freeze-dried.
- the degree of O-acetylation was about 50%, compared to the maximum possible yield of 200%.
- the OAcPec was subjected again to the same procedure.
- the final product was passed through a 2.5 x 50 cm column of Sephadex® G-50 in PFW and the void volume peak was passed through a sterile 0.45 micron membrane and freeze-dried. This preparation contained ⁇ 1.6 moles of O-acetyl/mole GalA or 80% yield.
- the molar content of the O-acetyl groups are determined by Hestrin reaction (12).
- the distribution of the O-acetyl groups are studied by the methyl resonances of 13 C NMR spectroscopy (Fig. 2).
- the antigenicity of the O-acetylated pectin was studied by reaction with the antiserum against Salmonella typhi in 2-dimensional immunodiffusion using Vi polysaccharide as a comparison. Immunodiffusion was performed in 1% agarose in PBS with B-260 antiserum. Quantitative precipitation was performed with 100 ⁇ L of B-260 with equal volumes of antigen, containing 1 to 100 ⁇ g/mL, at 37°C for 1 hour and at 3-8°C for five days with occasional mixing. The precipitates were washed in cold PFS three times, dissolved in 0.8% SDS and their A 280 recorded [23]. Serum Vi antibodies were measured by ELISA using a pooled hyperimmune mouse sera, quantitated by radioimmunoassay, as the standard [1].
- O-acetyl groups are studied at various temperatures for various periods of time.
- OAcPec and Vi (1 mg/mL) in PBS, pH 7.0, were incubated at 3-8°C, 25°C, 37°C and 60°C. Aliquots were removed at 1, 2, and 12 wks and analyzed for their content of O-acetyl and molecular size by gel filtration.
- Thiolation was measured on an aliquot of the polysaccharides treated with 0.1 M DTT at room temperature for 1 hour and passage through a 2.5x35 cm P10 column. Void volume fractions were titrated for their sulfhydryl content and the degree of derivatization expressed as percent cystamine.
- SPDP in absolute ethanol, was added dropwise at room temperature with stirring to protein (5 mg/mL) in 0.15M HEPES, 0.001 M EDTA, pH 7.5 (HE buffer) to a final concentration of 0.04M. The reaction proceeded for 1 hour and dialyzed against the HE buffer overnight. The reaction mixture was passed through a 2.5x35 cm column of P10 in HE buffer and the void volume fractions concentrated to ⁇ 10 mg/mL. An aliquot was treated with 0.075 M DTT at room temperature for 2 hours and its A 343 used to calculate the molar ratio of SPDP to protein [5].
- the cystamine-derivatized polysaccharide 10 mg/mL PBS, pH 7.4, was treated with 0.05M DTT at room temperature for two hours and passed through a 2.5x35 cm column of Sephadex® G-50 in PBS, pH 7.0. An aliquot was taken to determine its sulfhydryl content and the remainder mixed with an equal weight of SPDP-derivatized protein and stirred at room temperature for 4 hours and at 3-8°C overnight. The reaction mixture was passed through a 2.5x95 cm column of Sephacryl® S-1000 in PFS at 3-8°C.
- OAcPec-TT fractions containing protein and polysaccharide were pooled into two batches: OAcPec-TT 1 for the void volume peak and OAcPec-TT 2 for the lower molecular weight fractions.
- Vi-rEPA was passed through a 2.5x95 cm column of Sephacryl® S-1000 in PFS and the void volume fractions pooled.
- O-acetylation ranged from 0.1 to 1.6 moles/GalA for pectins. Unless specified, the OAcPec described in the following had 1.6 mole O-acetyl/mole GalA. 13 C N.M.R. of OAcPec showed more than two signals observed with acetyl methyl resonances indicating that mono and diacetylated species are present: non-O-acetylated residues could, however, be present ( Figure 2). The stoichiometry of C 2 and C 3 O-acetylation are the same. Therefore, the O-acetyl groups are probably distributed equally between C 2 and C 3 (Fig. 2), at least 60% of the GalA are di-O-acetylated, while 20% are mono-O-acetylated. Neutral sugar content in the pectin is lower than 5%.
- the M r of OAcPec similar to that of the pectin, had a broad distribution with the major peak ⁇ 400 kD (Fig. 3). Unlike pectin, OAcPec was soluble in 0.15M NaCl and did not form a gel in the presence of Ca ++ . Molar absorbances in the carbazole assay were 1.32x10 3 for OAcPec, 1.61x10 3 for pectin and 1.63x10 3 for GalA. The differences between pectin and GalA were ⁇ 2% and are probably due to neutral sugars in the pectin. Vi, in contrast, did not react in the carbazole assay.
- Pectin did not react with B-260 serum in double immunodiffusion.
- OAcPec in contrast, formed a line of identity with Vi (Fig. 4).
- Precipitation of OAcPec with Vi antiserum did not change with different counter ions including Na + , Ca ++ , K + or tetrabutylammonium.
- pectin also yielded a line of identity with the Vi (not shown).
- No precipitation in double immunodiffusion was observed when the O-acetylation of pectin was ⁇ 0.2 mole/mole GalA. Quantitative precipitation showed that both Vi and OAcPec precipitated 2.6 mg/mL Ab from B-260 antiserum (Fig. 5).
- thermostability of OAcPec and Vi O-acetyls was similar for OAcPec compared to Vi (Fig. 6). Following storage at 3-8°C for 12 weeks, there was no change in the concentration of O-acetyls for Vi and OAcPec compared to the original level of O-acetyls for Vi and OAcPec prior to storage: at 22°C, O-acetyls declined to 93% for Vi and to 88% for OAcPec and at 60°C, only 12% of the O-acetyls remained on Vi and 10% on OAcPec.
- the degree of thiolation was 4% for the O-acetylated pectin.
- the HPLC profile of OAcPec-TT shows the conjugate and a small portion of OAcPec were eluted in the void volume (Fig. 3). In several experiments (not shown) the final yield of the conjugate was 20-30%.
- the polysaccharide-protein ratio is ⁇ 0.4 -0.8% wt/wt.
- mice 16-20 g ⁇ general purpose mice from the NIH colony were injected subcutaneously 1, 2, or 3 times at 2 week intervals with 2.5 ⁇ g of the polysaccharide alone or as a conjugate. 10 mice from each group were exsanguinated two weeks after the first injection and one week after the second and third injections. Controls included mice injected with saline, Vi or OAcPec. Vi antibody levels were measured by ELISA with a reference calibrated by RIA.
- BSA bovine serum albumin
- Na 2 CO 3 sodium bicarbonate
- sodium chloride Brij® 35; Na N 3 ; Tris-HC-MgCl 2 ; HCl; PBS.
- Vi antibodies As reported, Vi elicited serum antibodies in mice after one injection and reinjection did not elicit a booster response [14,22-25]. Neither the pectin nor the OAcPec elicited Vi antibodies after any injections. After one injection, the Vi and OAcPec conjugates elicited similar levels of antibodies. Following the second injection, the conjugates elicited a booster response (P ⁇ 0.001) with the geometric mean antibody levels highest for Vi-rEPA (17.1) > OAcPec-TT 2 (7.65) > OAcPec-TT 1 (5.47). These differences, however, were not statistically significant. The third injection of all 3 conjugates did not elicit a booster response.
- GM geometric mean
- Vi antibodies ( ⁇ g Ab/mL serum) in mice immunized with Vi, Vi-rEPA, Pectin, O-acetyl Pectin (OAcPec) and OAcPec-TT conjugates.
- modified pectin, modified D-galacturonan, oligogalacturonate and polygalacturonate-carrier conjugates vaccines are tested as per WHO requirements for acellular vaccines against Salmonella typhi (32).
- Volunteers between 18 and 45 years of age, who have no antibodies to hepatitis B and to HIV-1 are recruited. Following receipt of their informed consent, volunteers receive 1 injection of Vi (25 ⁇ g in 0.5 mL) (1,13) or 1 injection of a modified pectin-carrier conjugate (25 ⁇ g polysaccharide in 0.5 mL) of the present invention intramuscularly. Oral temperature is taken and the injection site of each volunteer is inspected 6, 24 and 48 hours after each injection. Volunteers receive a second injection at 6 weeks and are bled 2 weeks later and 26 weeks after the first injection. Antibodies reactive to Vi are determined by ELISA as described herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Composition of conjugates of O-acetylated pectin (OAcPec) with tetanus toxoid (TT) and Vi with Pseudomonas aeruginosa recombinant Exoprotein A (rEPA). | ||||
Conjugate | Mr Ps (kD) | Cysteamine/PS(%) | SPDP/protein molar ratio | Ps/protein ratio(wt/wt) |
OAcPect-TT1 | 400 | 4.0 | 3.6 | 0.4 |
OAcPect-TT2 | 400 | 4.0 | 3.6 | 0.8 |
Vi-rEPA | 2x103 | 1.3 | 2.1 | 0.2 |
Vi antibodies (µg Ab/mL serum) in mice immunized with Vi, Vi-rEPA, Pectin, O-acetyl Pectin (OAcPec) and OAcPec-TT conjugates. | |||
Geometric Mean [n=10] | |||
Immunogen | 1st Injection | 2nd Injection | 3rd Injection |
Vi | 0.65 | 0.76 | Not Done |
Vi-rEPA | 0.85a | 17.1b | 12.7c |
Pectin | <0.03 | <0.03 | Not Done |
OAcPec | <0.03 | 0.04 | Not Done |
OAcPec-TT1 | 0.98d | 5.47e | 6.29f |
OAcPec-TT2 | 0.87g | 7.65h | 5.29i |
b, c vs a, P=0.0002, f,e vs d, P=0.0001, h vs g, P= 0.0002, i vs g, P=0.007, b vs c, f vs e, h vs i, b vs e or h, c vs f,i, NS. |
Claims (36)
- A method to prepare an immunogenic modified oligogalacturonate or polygalacturonate-carrier conjugate against Salmonella typhi comprising:(a) O-acetylating an oligogalacturonate or a polygalacturonate, which are derived from a plant, fruit or a synthetic source, to form an O-acetylated oligogalacturonate or an O-acetylated polygalacturonate,(b) conjugating the O-acetylated oligogalacturonate or the O-acetylated polygalacturonate to a carrier to form the modified oligogalacturonate or modified polygalacturonate-carrier conjugate which is immunogenic against Salmonella typhi.
- The method acccrding to claim 1 wherein the O-acetylated oligogalacturonate or the O-acetylated polygalacturonate is at least 50% O-acetylated.
- The method according to claim 1 or 2, wherein the O-acetylated oligogalacturonate or the O-acetylated polygalacturonate is about 80% to about 200% O-acetylated.
- The method according to any one of claims 1 to 3, wherein the O-acetylated oligogalacturonate or the 0-acetylated polygalacturonate is about 160% to about 190% O-acetylated.
- The method according to any one of claims 1 to 4, wherein the method provides at least 0.5 mole of O-acetyl per mole of galacturonate of the O-acetylated oligogalacturonate or the O-acetylated polygalacturonate.
- The method according to any one of claim 1 to 5, wherein the method provides at least 1.6 moles of O-acetyl per mole of galacturonate of the O-acetylated oligogalacturonate or the O-acetylated polygalacturonate.
- The method according to any one of claims 1 to 6, wherein the method provides about 1.6 to about 1.9 moles of O-acetyl per mole of galacturonate of the O-acetylated oligogalacturonate or the O-acetylated polygalacturonate.
- The method according to any one of claim 1 to 7, wherein the acetylation occurs at position C2, C3 or C2 and C3 on a galacturonic acid subunit of oligogalacturonate or polygalacturonate.
- The method of any one of claim 1 to 8, wherein the oligogalacturonate or polygalacturonate is pectin isolated from plants or fruits.
- The method of any one of claims 1 to 9 wherein the carrier is a protein selected from the group consisting of bacterial protein, viral protein, tetanus toxoid, tetanus toxin, diphtheria toxin, Pseudomonas aeruginosa exotoxin, Pseudomonas aeruginosa toxoid, pertussis toxin, pertussis toxoid, Clostridium perfringens exotoxin, Clostridium perfringens toxoid, hepatitis B surface antigen, hepatitis B core antigen and Pseudomonas exoprotein A or is a water insoluble carrier selected from the group consisting of aminoalkyl-Sepharose® , amino propyl-Sepharose® , aminohexyl-Sepharose® , and amino propyl glass.
- The method of any one of claims 1 to 10 wherein the oligogalacturonate or polygalacturonate is O-acetylated in organic solvents with acetig anhydride.
- The method of any one of claims 1 to 11 wherein the O-acetylated oligogalacturonate or polygalacturonate is derivatized with a homobifunctional or a heterobifunctional cross-linking agent or is thiolated and linked to a carrier containing a sulfhydro group or is aminolated and linked to a carrier containing a carboxyl group.
- The method of claim 12 wherein the agent is selected from the group consisting of N-succinimidyl 3-(2-pyridyldithio) propionate, adipic dihydrazide, cystamine, 3,3'dithiodipropionic acid, ethylene diamine, N-(2-iodoacetyl)-b-alaninate-propionate and succinimidyl 4-(N-Maleimido-methyl) ) cyclohexane-1-carboxylate.
- An immunogenic modified oligogalacturonate or polygalacturonate carrier conjugate against Salmonella typhi obtainable according to the method of claim 1 or 6.
- An immunogenic modified oligogalacturonate or polygalacturonate carrier conjugate against Salmonella typhi obtainable according to the method of claim 8 wherein the carrier is tetanus toxoid.
- An immunogenic modified oligogalacturonate or polygalacturonate carrier conjugate against Salmonella typhi obtainable according to the method of claim 9 wherein the pectin is at least 50% O-acetylated, at least 80% O-acetylated or about 160% to about 190% O-acetylated.
- An immunogenic modified oligogalacturonate or polygalacturonate carrier conjugate against Salmonella typhi obtainable according to the method of claim 12 wherein the crosslinking agent is cystamine.
- A pharmaceutical composition comprising the conjugate of any one of claims 14 to 17 and a pharmaceutically acceptable diluent.
- A modified saccharide-carrier conjugate which is immunogenic against Salmonella typhi comprising a saccharide selected from the group consisting of pectin, D-galacturonan, oligogalacturonate, polygalacturonate and mixtures thereof, wherein said saccharide is derived from a plant, fruit or a synthetic source, said saccharide is modified by O-acetylation, and said saccharide is covalently linked to a carrier.
- The modified saccharide-carrier conjugates of claim 19 wherein the saccharide is at least 50% O-acetylated, at least 80% o-acetylated or about 160% to about 190% O-acetylated.
- The modified saccharide-carrier conjugate of claim 19 or 20 wherein at least the C2, C3, or C2 and C3 position on a saccharide subunit is O-acetylated.
- The modified saccharide-carrier conjugate of any one of claims 19 to 21 wherein the modified saccharide has a molar ratio of O-acetyl groups: mole galacturonate of at least 0.5:1 or of at least 1.6:1.
- The modified saccharide-carrier conjugate of any one of claims 19 to 22 wherein the modified saccharide has a molar ratio of O-acetyl groups per mole galacturonate of between about 1.6 to about 1.9 moles of O-acetyl per mole of galacturonate.
- The modified saccharide-carrier conjugate of any one of claims 19 to 23 wherein the carrier is selected from the group consisting of bacterial protein, viral protein, tetanus toxoid, diphtheria toxin, Pseudomonas aeruginosa exotoxin, Pseudomonas aeruginosa toxoid, pertussis toxin, pertussis toxoid, Clostridium perfringens exotoxin, Clostridium perfringens toxoid, hepatitis B surface antigen, hepatitis B core antigen and Pseudomonas exoprotein A.
- The modified saccharide-carrier conjugate of any one of claims 19 to 24 wherein the saccharide is linked to the carrier by a homobifunctional or heterobifunctional cross-linking agent.
- The modified saccharide-carrier conjugate of claim 25 wherein the crosslinking agent is selected from the group consisting of adipic dihydrazide, ethylene diamine, cystamine, N-succinimidyl-3-(2-pyridyldithio) propionate, N-succinimidyl N-(2-iodoacetyl)-b-alaninate-propionate, succinimidyl 4-(N-Maleimido-methyl) cyclohexane-1-carboxylate, and 3,3'-dithiodipropionic acid.
- The modified saccharide-carrier conjugate of any one of claims 19 to 26 wherein the modified saccharide has a subunit structure substantially identical to a subunit structure of Vi from Salmonella typhi.
- An immunogen against Salmonella typhi comprising: a plant, fruit or synthetic saccharide modified by O-acetylation covalently linked to a carrier, wherein said modified saccharide-carrier conjugate elicits antibodies in mammals, and said antibodies are specifically immunoreactive against Vi of Salmonella typhi.
- The immunogen of claim 28 wherein the modified plant, fruit or synthetic saccharide has immunological identity with the Vi of Salmonella typhi as measured by immunodiffusion.
- The immunogen of claim 28 or 29 wherein the plant or fruit saccharide is derived from citrus fruit, apples, or beets.
- The immunogen of any one of claims 28 to 30 wherein the saccharide is pectin or is selected from the group consisting of D-galacturonan, oligogalacturonate, polygalacturonate, and mixtures thereof.
- The immunogen of any one of claims 28 to 31 wherein the carrier is selected from the group consisting of bacterial protein, viral protein, tetanus toxoid, diphtheria toxin, Pseudomonas aeruginosa exotoxin, Ps. aeruginosa toxoid, pertussis toxin, pertussis toxoid, Clostridium perfringens exotoxin, Clostridium perfringens toxoid, hepatitis B surface antigen, hepatitis B core antigen and Pseudomonas exoprotein A.
- The immunogen of any one of claims 28 to 32 wherein the saccharide is at least 50% O-acetylated.
- The immunogen of any one of claims 31 to 33 wherein the pectin is at least 80% O-acetylated.
- A vaccine against typhoid fever comprising the immunogen of any one of claims 28 to 34 and a pharmaceutically acceptable diluent.
- Use of an O-acetylated plant, fruit or synthetic saccharide linked to a carrier for the preparation of a medicament for use in a method of actively immunizing a human against typhoid fever comprising: administering in vivo a sufficient amount of an O-acetylated plant, fruit or synthetic saccharide linked to a carrier, wherein said amount is sufficient to elicite antibody that binds to Vi of Salmonella typhi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/323,918 US5738855A (en) | 1994-10-17 | 1994-10-17 | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
US323918 | 1994-10-17 | ||
PCT/US1995/012585 WO1996011709A1 (en) | 1994-10-17 | 1995-09-28 | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0787015A1 EP0787015A1 (en) | 1997-08-06 |
EP0787015B1 true EP0787015B1 (en) | 2002-02-27 |
Family
ID=23261276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95935689A Expired - Lifetime EP0787015B1 (en) | 1994-10-17 | 1995-09-28 | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
Country Status (7)
Country | Link |
---|---|
US (1) | US5738855A (en) |
EP (1) | EP0787015B1 (en) |
KR (1) | KR100433986B1 (en) |
AT (1) | ATE213647T1 (en) |
AU (1) | AU3760795A (en) |
DE (1) | DE69525638T2 (en) |
WO (1) | WO1996011709A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69612205T2 (en) * | 1996-12-16 | 2001-08-30 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for coupling polysaccharides and proteins |
ES2245805T3 (en) * | 1997-10-03 | 2006-01-16 | Galenica Pharmaceuticals, Inc. | POLISACARIDS FORMING IMINAS, PREPARATION OF THE SAME AND THE USE OF THE SAME AS ASSISTANTS OF IMMUNO STIMULANTS. |
US6258774B1 (en) * | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
US6797275B1 (en) * | 1998-12-04 | 2004-09-28 | The United States Of America As Represented By The Department Of Health And Human Services | Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine |
BR9916522A (en) | 1998-12-23 | 2002-12-24 | Thompson Boyce Plant Res | Vector of expression of plants, cell, plant seed, polynucleotide, immunogenic composition, methods to elicit an immune response in a mammal and to isolate polypeptide, and transgenic plant or plant cell |
CA2434668A1 (en) | 2003-07-04 | 2005-01-04 | Laurence Mulard | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
CN1645104B (en) * | 2004-12-21 | 2011-03-16 | 兰州生物制品研究所 | Method for determining polymer content in Vi-rEPA combined vaccine of typhoid |
US8426567B2 (en) * | 2005-08-26 | 2013-04-23 | Econugenics, Inc. | Method for enhancing mammalian immunological function |
GB0810894D0 (en) | 2008-06-13 | 2008-07-23 | Novartis Vaccines & Diagnostic | Conjugated saccharide |
EP2386563A1 (en) | 2010-05-12 | 2011-11-16 | Institut Pasteur | Novel O-acetylated decasaccharides |
US10046039B2 (en) | 2013-08-24 | 2018-08-14 | Bharat Biotech International Limited | Bacterial vaccine and methods for manufacture thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204098A (en) * | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
FR2682388B1 (en) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | PROCESS FOR THE PREPARATION OF AN OLIGOSIDE BY DEPOLYMERIZATION OF A POLYOSIDE DERIVED FROM A PATHOGENIC AGENT, OLIGOSIDE THUS OBTAINED AND ITS USE IN PARTICULAR AS A VACCINE AGENT. |
IL102687A (en) * | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
-
1994
- 1994-10-17 US US08/323,918 patent/US5738855A/en not_active Expired - Lifetime
-
1995
- 1995-09-28 DE DE69525638T patent/DE69525638T2/en not_active Expired - Lifetime
- 1995-09-28 AU AU37607/95A patent/AU3760795A/en not_active Abandoned
- 1995-09-28 EP EP95935689A patent/EP0787015B1/en not_active Expired - Lifetime
- 1995-09-28 KR KR1019970702529A patent/KR100433986B1/en not_active IP Right Cessation
- 1995-09-28 WO PCT/US1995/012585 patent/WO1996011709A1/en active IP Right Grant
- 1995-09-28 AT AT95935689T patent/ATE213647T1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO1996011709A1 (en) | 1996-04-25 |
EP0787015A1 (en) | 1997-08-06 |
KR100433986B1 (en) | 2004-09-13 |
AU3760795A (en) | 1996-05-06 |
ATE213647T1 (en) | 2002-03-15 |
US5738855A (en) | 1998-04-14 |
DE69525638T2 (en) | 2002-10-17 |
KR970706845A (en) | 1997-12-01 |
DE69525638D1 (en) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6372222B1 (en) | Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof | |
AU601742B2 (en) | Immunogenic conjugates | |
KR100704826B1 (en) | Immunogenic ?-Propionamido-Linked Polysaccharide Protein Conjugate Useful as a Vaccine Produced Using an N-Acryloylated Polysaccharide | |
Theilacker et al. | Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine | |
CA2142981C (en) | Vaccines against group c neisseria meningitidis | |
US8168195B2 (en) | Vaccines against Escherichia coli O157 infection | |
EP0787015B1 (en) | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide | |
US9173932B2 (en) | Vibrio cholerae O139 conjugate vaccines | |
AU767047B2 (en) | Vaccines against (escherichia coli) O157 infection | |
RU2249463C2 (en) | Immunogenic conjugate of beta-propionamide-bound polysaccharide with protein applied as vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970520 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19990625 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020227 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020227 |
|
REF | Corresponds to: |
Ref document number: 213647 Country of ref document: AT Date of ref document: 20020315 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69525638 Country of ref document: DE Date of ref document: 20020404 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020527 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020527 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020527 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020930 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20021128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030401 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, A Free format text: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES#C/O NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER, 6011 EXECUTIVE BOULEVARD, SUITE 325#ROCKVILLE, MD 20852-3804 (US) -TRANSFER TO- THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES#C/O NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER, 6011 EXECUTIVE BOULEVARD, SUITE 325#ROCKVILLE, MD 20852-3804 (US) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20140929 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20140929 Year of fee payment: 20 Ref country code: FR Payment date: 20140917 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20140924 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20140929 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20140926 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20140929 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69525638 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20150927 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20150927 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20150927 |